Protease Inhibitors: all 1,856 studies that test it
Page 10 of 19. Open to participants first (69), then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1CompletedNCT04246723Phase 2
- Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPFWithdrawnNCT04244825Phase 2
- A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate AgentsTerminatedNCT04236453Phase 1
- Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)WithdrawnNCT04235049Phase 4
- Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM PatientsCompletedNCT04217967Phase 4
- A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy ParticipantsCompletedNCT04208061Phase 1
- Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"TerminatedNCT04204252Phase 3
- Inflammation and Co-Infections in D²EFTWithdrawnNCT04183738Phase 4
- A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I PatientsCompletedNCT04155515Phase 3
- Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV InfectionCompletedNCT04147208Phase 2
- A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test MedicinesCompletedNCT04137341Phase 1
- A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an InjectionCompletedNCT04136327Phase 1
- A Pilot Study of BXCL701 in Patients With Pancreatic CancerWithdrawnNCT04123574Early Phase 1
- A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101CompletedNCT04111666Phase 1
- Ixazomib + Pomalidomide + Dexamethasone In MMActive, not recruitingNCT04094961Phase 1/2
- SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis CStatus unknownNCT04070235Phase 2/3
- RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled InfectionStatus unknownNCT04064632Phase 4
- Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.Status unknownNCT04050098Phase 1
- Bone Healing During Ninlaro ExposureCompletedNCT04028115Phase 2
- Protective Effect in Cardiac Surgery PatientsStatus unknownNCT04028024Not applicable
- Transplantation Using Hepatitis C Positive Donors, A Safety TrialStatus unknownNCT04017338Phase 3
- Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMActive, not recruitingNCT04009109Phase 2
- Healthy Volunteer Study Comparing Tablet and Capsule FormulationsWithdrawnNCT04001998Phase 1
- Nucleosides And Darunavir/Dolutegravir In AfricaStatus unknownNCT03988452Phase 3
- MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell TransplantationWithdrawnNCT03986086Phase 1/2
- Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune CytopeniaWithdrawnNCT03965624Phase 2
- Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT03942224Phase 2
- A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.CompletedNCT03910660Phase 1/2
- Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)WithdrawnNCT03888534Phase 1
- Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients SeraStatus unknownNCT03882307Early Phase 1
- Selinexor in Combination With Ixazomib for the Treatment of Advanced SarcomaWithdrawnNCT03880123Phase 1
- Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)CompletedNCT03833362Phase 3
- A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched VolunteersCompletedNCT03832426Phase 1
- Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03829020Phase 1
- The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell TransplantTerminatedNCT03805789Phase 2/3
- ATTIC - Access To Treat in the CommunityTerminatedNCT03797066Phase 4
- A Prospective Cohort Study to Improve HCV Care in Dialysis PatientsWithdrawnNCT03791814Phase 4
- RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft FunctionStatus unknownNCT03791476Phase 1
- Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03763162Phase 2
- Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple MyelomaTerminatedNCT03757221Phase 2
- A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy SubjectsCompletedNCT03748745Phase 1
- Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CFCompletedNCT03748199Phase 1/2
- Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT03746652Phase 2
- Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM PatientsTerminatedNCT03733691Phase 2
- Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
- Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple MyelomaCompletedNCT03731832Phase 2
- Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney TransplantationTerminatedNCT03723824Phase 4
- Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT03720041Phase 3
- Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2aCompletedNCT03719313Phase 3
- A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND StudyCompletedNCT03710252Phase 4
- Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected PatientsWithdrawnNCT03708861Phase 3
- Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of MetforminCompletedNCT03686722Phase 1
- EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONSCompletedNCT03683524Phase 4
- Body Composition Sub-study of the D2EFT TrialCompletedNCT03675815Phase 4
- Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG TreatmentCompletedNCT03672240Phase 1/2
- Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple MyelomaStatus unknownNCT03669445Phase 2
- A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy SubjectsCompletedNCT03662568Phase 1
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03651128Phase 3
- The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate CapsulesCompletedNCT03638076Phase 2
- A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.CompletedNCT03636347Phase 2
- Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney TransplantWithdrawnNCT03623568Phase 4
- Ixazomib Maintenance Study in Patients With AL AmyloidosisActive, not recruitingNCT03618537Phase 2
- To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese VolunteersCompletedNCT03610880Phase 1
- To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349CompletedNCT03610867Phase 1
- A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell TransplantationWithdrawnNCT03608501Phase 2
- Safety, Tolerability and Pharmacokinetic Profile of an Infusion of Cilastatin in Healthy Volunteers.CompletedNCT03595189Phase 1
- Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple MyelomaTerminatedNCT03590652Phase 2
- Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive ImplantStatus unknownNCT03589040Phase 2
- Darunavir and Rilpivirine Interactions With Levonorgestrel ImplantStatus unknownNCT03589027Phase 2
- Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney CancerCompletedNCT03587662Phase 2
- A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease RiskWithdrawnNCT03585101Phase 4
- First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver FibrosisCompletedNCT03559166Phase 1
- Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir FailureCompletedNCT03549832Not applicable
- Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C VirusStatus unknownNCT03540212Phase 2/3
- Subcutaneous Elafin in Healthy SubjectsCompletedNCT03522935Phase 1
- BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple MyelomaTerminatedNCT03502577Phase 1
- Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney DiseaseCompletedNCT03499639Phase 4
- Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected PatientsCompletedNCT03496233Phase 3
- A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgramsCompletedNCT03492112Not applicable
- Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial InfarctionCompletedNCT03486080Phase 2
- Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1bCompletedNCT03485846Phase 2
- A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedNCT03430830Phase 1
- Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or LymphomaWithdrawnNCT03422874Phase 1
- A Multiple Ascending Dose Study of COR388CompletedNCT03418688Phase 1
- Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple MyelomaCompletedNCT03399539Phase 1
- Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma PatientsCompletedNCT03387774Phase 3
- Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4WithdrawnNCT03381859Phase 4
- Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency VirusCompletedNCT03369327Phase 3
- Toward Elimination of Hepatitis C Virus (HCV): A Pilot StudyStatus unknownNCT03364725Phase 4
- Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.CompletedNCT03362814Phase 2/3
- Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney TransplantStatus unknownNCT03359746Phase 4
- Study of COR388 HCl in Healthy SubjectsCompletedNCT03331900Phase 1
- A Study With GLPG1972 in Osteoarthritis SubjectsCompletedNCT03311009Phase 1
- Effect Of DAAs For Treatment Of HCV On Normal KidneyStatus unknownNCT03296930Phase 4
- Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedNCT03288636Phase 1
- Daratumumab, Ixazomib, and Dexamethasone in AL AmyloidosisCompletedNCT03283917Phase 1
- Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of CervixCompletedNCT03256916Phase 3
- Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 DiabetesCompletedNCT03254368Phase 2
- Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL AmyloidosisCompletedNCT03236792Phase 1/2
- Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.Active, not recruitingNCT03225417Phase 1/2